Live Vital Review

Live Vital, LLC is a cash-pay telehealth provider for compounded GLP-1, peptide, and longevity protocols. Patients can complete a guided intake online or book a free fifteen-minute telephone consultation. The provider says Patrick R. Taylor, MD reviews each intake and determines whether a prescription is appropriate.

The named physician is verifiable. The federal NPI registry lists Patrick R. Taylor, MD with an active family-medicine taxonomy and a Utah medical-license number, and the University of Utah Health profile independently matches his family-medicine background. That confirms the identity and Utah credential, but it does not by itself verify licensure in every state where the site markets care.

The online intake is advertised as taking ten to fifteen minutes. Live Vital says physician review generally takes twenty-four to forty-eight hours. Once approved, the prescription goes to a licensed U.S. pharmacy for compounding and testing. The site estimates five to ten days from intake to starting treatment and describes overnight cold-pack shipment after processing.

Compounded semaglutide is advertised at $99 per month and $299 total for ten weeks. The exact total divided across three stated monthly billing units is $99.67, so the compact card rounds to Avg. $100/mo. Compounded tirzepatide is $183 per month and $549 total for ten weeks, or Avg. $183/mo. The pages do not explain the precise charge dates, whether ten weeks is treated as three subscription months, or what happens after the protocol ends. Both prices stay out of like-for-like leaderboard comparisons until that cadence is confirmed.

Compounded NAD+ is listed at $149 per month and $447 total for three months, so its compact figure is Avg. $149/mo. The product page does not publish one universal route, strength, dose, or vial quantity. Because those details can materially change both clinical use and value, NAD+ maps to the canonical ingredient but remains ineligible for direct price comparison.

The wider current menu includes GHK-Cu, BPC-157, TB-500, Wolverine, Glow, Klow, CJC-1295 plus ipamorelin, MOTS-c, tesamorelin, and glutathione. These remain consolidated editorial details rather than separate comparison cards. Glow is GHK-Cu plus BPC-157 and TB-500; Klow adds KPV; and Wolverine combines BPC-157 with TB-500. Product branding should not obscure the active ingredients.

The peptide consent is unusually direct about uncertainty. It says treatment may be experimental, controversial, off-label, and unapproved, and it acknowledges limited or evolving scientific evidence. That disclosure is useful, but consent does not resolve whether a specific bulk substance is eligible for compounding, whether the advertised use is evidence-based, or whether the product is appropriate for an individual patient.

FDA has identified potential significant safety risks or limited human-safety information for several ingredients currently marketed by Live Vital. The agency's materials specifically discuss BPC-157, CJC-1295, ipamorelin, injectable GHK-Cu, KPV, MOTS-c, and TB-500. A federal advisory committee also recently reviewed BPC-157, KPV, TB-500, and MOTS-c for possible inclusion on the 503A bulks list. Consideration by a committee is not the same as approval or proof of safety.

The most serious conflict is in the public FAQ. Live Vital says some multi-dose vials may be used for six months after opening and that many patients use them longer. FDA currently recommends that patients discard multi-dose compounded GLP-1 vials within twenty-eight days after first use, even when the compounder says the vial can be used longer. Patients should not rely on generic website copy for sterility decisions and should seek current product-specific instructions from the dispensing pharmacy and prescriber.

A recently indexed Live Vital page advertised compounded retatrutide, but that URL now returns 404 and the product is absent from the current treatment menu and sitemap. FDA says retatrutide cannot be used in compounding under federal law. This review does not list it as a current offering, but the recent page is a reason to ask Live Vital for written confirmation that it is no longer available.

For compounded semaglutide and tirzepatide, current FDA policy requires an individual-patient prescription and restricts routine compounding of products that are essentially copies of commercially available drugs unless a prescriber documents a significant difference for that identified patient. Live Vital says each order receives physician review, but its public pages do not disclose the exact formulation, significant-difference rationale, or default pharmacy for an individual prescription.

Live Vital says medication, supplies, temperature-controlled tracked shipping, portal messaging, and protocol adjustments are included. Direct messaging replies are advertised within twenty-four hours and often the same day. The service is cash-pay, does not bill insurance directly, and says superbills may be available. HSA or FSA use depends on the patient's plan and tax rules.

The terms allow cancellation at any time, effective at the end of the current billing period. Consultation refunds are discretionary, and medication or laboratory charges are generally nonrefundable once ordered or dispensed. The peptide consent also says there are no refunds for treatment received regardless of results. Patients should confirm when the first charge occurs, whether a protocol renews, the cancellation deadline, and what is refundable if a clinician or pharmacy cannot proceed.

Live Vital markets service in all fifty states, while its terms narrow availability to locations where telehealth is permitted. This review confirmed the named physician's Utah credential but did not find a public multi-state clinician roster. Before treatment, a patient should verify the name and license of the clinician assigned in the patient's state and the license of the dispensing pharmacy.